Anti-CD30 and anti-CD3 bispecific antibodies and methods of immunotherapy for CD30+ malignancies

Patent metadata

Field	Value
Publication number	US-12391764-B2
Application number	US-202318301924-A
Country	US
Kind code	B2
Filing date	Apr 17, 2023
Priority date	Sep 24, 2018
Publication date	Aug 19, 2025
Grant date	Aug 19, 2025

Abstract

The present invention provides novel bispecific antibodies that bind to human CD30 and uses thereof. Methods of treating cancer using the bispecific antibodies described herein are also provided.

First claim

The invention claimed is:

1. An isolated bispecific antibody capable of binding human CD30 and to CD3 comprising an anti-CD30 antibody or antigen binding portion thereof and an anti-CD3 antibody or antigen binding portion thereof, wherein the anti-CD30 antibody or antigen binding portion thereof comprises:
(a) a light chain variable domain comprising a CDRL1 region of SEQ ID NO:_2 or a sequence with at least 90% similarity to SEQ ID NO:_2, a CDRL2 region of SEQ ID NO:_3 or a sequence with at least 90% similarity to SEQ ID NO:_3, and a CDRL3 region of SEQ ID NO:_4 or a sequence with at least 90% similarity to SEQ ID NO:_4 and a heavy chain variable domain comprising a CDRH1 region of SEQ ID NO:_6 or a sequence with at least 90% similarity to SEQ ID NO:_6, a CDRH2 region of SEQ ID NO:_7 or a sequence with at least 90% similarity to SEQ ID NO:_7, and a CDRH3 region of SEQ ID NO:_8 or a sequence with at least 90% similarity to SEQ ID NO:_8;
(b) a light chain variable domain comprising a CDRL1 region of SEQ ID NO: 10 or a sequence with at least 90% similarity to SEQ ID NO: 10, a CDRL2 region of SEQ ID NO: 11 or a sequence with at least 90% similarity to SEQ ID NO: 11, and a CDRL3 region of SEQ ID NO:_12 or a sequence with at least 90% similarity to SEQ ID NO: 12 and a heavy chain variable domain comprising a CDRH1 region of SEQ ID NO: 14 or a sequence with at least 90% similarity to SEQ ID NO:_14, a CDRH2 region of SEQ ID NO:_15 or a sequence with at least 90% similarity to SEQ ID NO:_15, and a CDRH3 region of GAY or a sequence with at least 90% similarity to GAY;
(c) a light chain variable domain comprising a CDRL1 region of SEQ ID NO:_18 or a sequence with at least 90% similarity to SEQ ID NO: 18, a CDRL2 region of SEQ ID NO: 19 or a sequence with at least 90% similarity to SEQ ID NO: 19, and a CDRL3 region of SEQ ID NO:_20 or a sequence with at least 90% similarity to SEQ ID NO:_20 and a heavy chain variable domain comprising a CDRH1 region of SEQ ID NO:_22 or a sequence with at least 90% similarity to SEQ ID NO:_22, a CDRH2 region of SEQ ID NO:_23 or a sequence with at least 90% similarity to SEQ ID NO: 23, and a CDRH3 region of SEQ ID NO:_24 or a sequence with at least 90% similarity to SEQ ID NO:_24;
(d) a light chain variable domain comprising a CDRL1 region of SEQ ID NO:_26 or a sequence with at least 90% similarity to SEQ ID NO: 26, a CDRL2 region of SEQ ID NO:_27 or a sequence with at least 90% similarity to SEQ ID NO:_27, and a CDRL3 region of SEQ ID NO:_28 or a sequence with at least 90% similarity to SEQ ID NO:_28 and a heavy chain variable domain comprising a CDRH1 region of SEQ ID NO:_30 or a sequence with at least 90% similarity to SEQ ID NO:_30, a CDRH2 region of SEQ ID NO:_31 or a sequence with at least 90% similarity to SEQ ID NO:_31, and a CDRH3 region of SEQ ID NO:_32 or a sequence with at least 90% similarity to SEQ ID NO:_32; or
(e) a light chain variable domain comprising a CDRL1 region of SEQ ID NO:_34 or a sequence with at least 90% similarity to SEQ ID NO:_34, a CDRL2 region of SEQ ID NO:_35 or a sequence with at least 90% similarity to SEQ ID NO:_35, and a CDRL3 region of SEQ ID NO:_36 or a sequence with at least 90% similarity to SEQ ID NO:_36 and a heavy chain variable domain comprising a CDRH1 region of SEQ ID NO:_38 or a sequence with at least 90% similarity to SEQ ID NO:_38, a CDRH2 region of SEQ ID NO:_39 or a sequence with at least 90% similarity to SEQ ID NO:_39, and a CDRH3 region of SEQ ID NO:_40 or a sequence with at least 90% similarity to SEQ ID NO:_40.

2. The isolated bispecific antibody of claim 1 , wherein the anti-CD30 antibody or antigen binding portion thereof comprises:
(a) a light chain variable domain comprising a CDRL1 region of SEQ ID NO:_2 or a sequence with at least 95% similarity to SEQ ID NO:_2, a CDRL2 region of SEQ ID NO:_3 or a sequence with at least 95% similarity to SEQ ID NO:_3, and a CDRL3 region of SEQ ID NO:_4 or a sequence with at least 95% similarity to SEQ ID NO:_4 and a heavy chain variable domain comprising a CDRH1 region of SEQ ID NO:_6 or a sequence with at least 95% similarity to SEQ ID NO:_6, a CDRH2 region of SEQ ID NO:_7 or a sequence with at least 95% similarity to SEQ ID NO:_7, and a CDRH3 region of SEQ ID NO:_8 or a sequence with at least 95% similarity to SEQ ID NO:_8;
(b) a light chain variable domain comprising a CDRL1 region of SEQ ID NO: 10 or a sequence with at least 95% similarity to SEQ ID NO: 10, a CDRL2 region of SEQ ID NO: 11 or a sequence with at least 95% similarity to SEQ ID NO: 11, and a CDRL3 region of SEQ ID NO:_12 or a sequence with at least 95% similarity to SEQ ID NO: 12 and a heavy chain variable domain comprising a CDRH1 region of SEQ ID NO: 14 or a sequence with at least 95% similarity to SEQ ID NO:_14, a CDRH2 region of SEQ ID NO:_15 or a sequence with at least 95% similarity to SEQ ID NO:_15, and a CDRH3 region of GAY or a sequence with at least 95% similarity to GAY;
(c) a light chain variable domain comprising a CDRL1 region of SEQ ID NO:_18 or a sequence with at least 95% similarity to SEQ ID NO: 18, a CDRL2 region of SEQ ID NO: 19 or a sequence with at least 95% similarity to SEQ ID NO: 19, and a CDRL3 region of SEQ ID NO:_20 or a sequence with at least 95% similarity to SEQ ID NO:_20 and a heavy chain variable domain comprising a CDRH1 region of SEQ ID NO:_22 or a sequence with at least 95% similarity to SEQ ID NO:_22, a CDRH2 region of SEQ ID NO:_23 or a sequence with at least 95% similarity to SEQ ID NO:_23, and a CDRH3 region of SEQ ID NO:_24 or a sequence with at least 95% similarity to SEQ ID NO:_24;
(d) a light chain variable domain comprising a CDRL1 region of SEQ ID NO:_26 or a sequence with at least 95% similarity to SEQ ID NO:_26, a CDRL2 region of SEQ ID NO:_27 or a sequence with at least 95% similarity to SEQ ID NO:_27, and a CDRL3 region of SEQ ID NO: 28 or a sequence with at least 95% similarity to SEQ ID NO:_28 and a heavy chain variable domain comprising a CDRH1 region of SEQ ID NO:_30 or a sequence with at least 95% similarity to SEQ ID NO:_30, a CDRH2 region of SEQ ID NO:_31 or a sequence with at least 95% similarity to SEQ ID NO:_31, and a CDRH3 region of SEQ ID NO:_32 or a sequence with at least 95% similarity to SEQ ID NO:_32; or
(e) a light chain variable domain comprising a CDRL1 region of SEQ ID NO:_34 or a sequence with at least 95% similarity to SEQ ID NO:_34, a CDRL2 region of SEQ ID NO:_35 or a sequence with at least 95% similarity to SEQ ID NO:_35, and a CDRL3 region of SEQ ID NO:_36 or a sequence with at least 95% similarity to SEQ ID NO:_36 and a heavy chain variable domain comprising a CDRH1 region of SEQ ID NO:_38 or a sequence with at least 95% similarity to SEQ ID NO:_38, a CDRH2 region of SEQ ID NO:_39 or a sequence with at least 95% similarity to SEQ ID NO:_39, and a CDRH3 region of SEQ ID NO:_40 or a sequence with at least 95% similarity to SEQ ID NO:_40.

3. The isolated bispecific antibody of claim 1 , wherein the anti-CD30 antibody or antigen binding portion thereof comprises:
(a) a light chain variable domain comprising a CDRL1 region of SEQ ID NO:_2 or a sequence with at least 98% similarity to SEQ ID NO:_2, a CDRL2 region of SEQ ID NO:_3 or a sequence with at least 98% similarity to SEQ ID NO:_3, and a CDRL3 region of SEQ ID NO:_4 or a sequence with at least 98% similarity to SEQ ID NO:_4 and a heavy chain variable domain comprising a CDRH1 region of SEQ ID NO:_6 or a sequence with at least 98% similarity to SEQ ID NO:_6, a CDRH2 region of SEQ ID NO:_7 or a sequence with at least 98% similarity to SEQ ID NO:_7, and a CDRH3 region of SEQ ID NO:_8 or a sequence with at least 98% similarity to SEQ ID NO:_8;
(b) a light chain variable domain comprising a CDRL1 region of SEQ ID NO: 10 or a sequence with at least 98% similarity to SEQ ID NO: 10, a CDRL2 region of SEQ ID NO: 11 or a sequence with at least 98% similarity to SEQ ID N

Assignees

• Medical College Of Wisconsin Inc
• Univ Virginia Patent Foundation
• Medical College Wisconsin Inc

Inventors

• Medin Jeffrey A
• Lum Lawrence G
• Oldham Robyn A A
• Thakur Archana

Classifications

• C07K14/7051

  T-cell receptor (TcR)-CD3 complex · CPC title

• C07K14/70578

  NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 (NGF-receptor C07K14/71, TNF-receptor C07K14/7151) · CPC title

• A61K39/39583

  against materials not provided for elsewhere, e.g. haptens, coenzymes · CPC title

• A61K39/3955

  against proteinaceous materials, e.g. enzymes, hormones, lymphokines · CPC title

• C07K2317/732

  Antibody-dependent cellular cytotoxicity [ADCC] · CPC title